KF4 Anti-Chymotrypsin-like Elastase 1 Antibody and Purified Alpha-1 Antitrypsin Have Similar but Not Additive Efficacy in Preventing Emphysema in Murine Alpha-1 Antitrypsin Deficiency

Alpha-1 antitrypsin (AAT) deficiency is the most common genetic cause of emphysema. Chymotrypsin-like Elastase 1 (CELA1) is a serine protease neutralized by AAT and is important in emphysema progression. Cela1-deficiency is protective in a murine models of AAT-deficient emphysema. KF4 anti-CELA1 ant...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Chronic obstructive pulmonary diseases 2024-11
Hauptverfasser: Devine, Andrew J, Smith, Noah J, Joshi, Rashika, Brooks-Patton, Brandon, Dunham, Jenna, Varisco, Ansley N, Goodman, Emily M, Fan, Qiang, Zingarelli, Basilia, Varisco, Brian M
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title Chronic obstructive pulmonary diseases
container_volume
creator Devine, Andrew J
Smith, Noah J
Joshi, Rashika
Brooks-Patton, Brandon
Dunham, Jenna
Varisco, Ansley N
Goodman, Emily M
Fan, Qiang
Zingarelli, Basilia
Varisco, Brian M
description Alpha-1 antitrypsin (AAT) deficiency is the most common genetic cause of emphysema. Chymotrypsin-like Elastase 1 (CELA1) is a serine protease neutralized by AAT and is important in emphysema progression. Cela1-deficiency is protective in a murine models of AAT-deficient emphysema. KF4 anti-CELA1 antibody prevented emphysema in porcine pancreatic elastase (PPE) and cigarette smoke models in wild type mice. We evaluated potential toxicities of KF4 and its ability to prevent emphysema in AAT deficiency. We found Cela1 protein expression in mouse lung, pancreas, small intestine, spleen, and bone marrow. In toxicity studies, mice treated with KF4 25 mg/kg weekly for four weeks showed an elevation in blood urea nitrogen and slower weight gain compared to lower doses or equivalent dose IgG. By histologic grading of tissue injury of the lung, kidney, liver, and heart, there was some evidence of liver injury with KF4 25 mg/kg, but in all tissues, injury was less than in control mice subjected to cecal ligation and puncture. In efficacy studies, KF4 doses as low as 0.5 mg/kg reduced the lung elastase activity of AAT-/- mice treated with 0.2 units of PPE. In this injury model, AAT-/- mice treated with KF4 1 mg/kg weekly, human purified AAT 60 mg/kg weekly, and combined KF4 and AAT treatment had less emphysema than mice treated with IgG 1 mg/kg weekly. However, the efficacy of KF4, AAT, or KF4 & AAT was similar. While KF4 might be an alternative to AAT replacement, combined KF4 and AAT replacement does not confer additional benefit.
doi_str_mv 10.15326/jcopdf.2024.0535
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_15326_jcopdf_2024_0535</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3146531084</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1415-831d0c6fea5260fb1eab303dfc25a72893efb17908031f702cbd1723babc26813</originalsourceid><addsrcrecordid>eNptkctOwzAQRS0EoqjwAWyQl2xS_IiTdFmVFhBPCZDYRY49pi55YSeV8mX8HukDxILVjGbuuZuD0CklIyo4iy6Wqqq1GTHCwhERXOyhI8ZjFowFe9v_sw_QifdLQghN4jih5BAN-DjiERHhEfq6nYd4UjY2mC66ompcV3tbBrn9ADzLpW-kB0w3iazSHZalxk-ts8aCxpO8Xshg-92R-FquAD_bwubS4axt8EPV4InWtrH9Y2aMVVJ1uE8-OVhBT5bveFbUi85DIdf3-76-hH_LL6HHLZSqO0YHRuYeTnZziF7ns5fpdXD3eHUzndwFioZUBAmnmqjIgBQsIiajIDNOuDaKCRmzZMyhP8ZjkhBOTUyYyjSNGc9kpliUUD5E59ve2lWfLfgmLaxXkOeyhKr1KadhJDglSdhH6TaqXOW9A5PWzhbSdSkl6UZZulWWrpWla2U9c7arb7MC9C_xI4h_A2fdlSY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3146531084</pqid></control><display><type>article</type><title>KF4 Anti-Chymotrypsin-like Elastase 1 Antibody and Purified Alpha-1 Antitrypsin Have Similar but Not Additive Efficacy in Preventing Emphysema in Murine Alpha-1 Antitrypsin Deficiency</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Devine, Andrew J ; Smith, Noah J ; Joshi, Rashika ; Brooks-Patton, Brandon ; Dunham, Jenna ; Varisco, Ansley N ; Goodman, Emily M ; Fan, Qiang ; Zingarelli, Basilia ; Varisco, Brian M</creator><creatorcontrib>Devine, Andrew J ; Smith, Noah J ; Joshi, Rashika ; Brooks-Patton, Brandon ; Dunham, Jenna ; Varisco, Ansley N ; Goodman, Emily M ; Fan, Qiang ; Zingarelli, Basilia ; Varisco, Brian M</creatorcontrib><description>Alpha-1 antitrypsin (AAT) deficiency is the most common genetic cause of emphysema. Chymotrypsin-like Elastase 1 (CELA1) is a serine protease neutralized by AAT and is important in emphysema progression. Cela1-deficiency is protective in a murine models of AAT-deficient emphysema. KF4 anti-CELA1 antibody prevented emphysema in porcine pancreatic elastase (PPE) and cigarette smoke models in wild type mice. We evaluated potential toxicities of KF4 and its ability to prevent emphysema in AAT deficiency. We found Cela1 protein expression in mouse lung, pancreas, small intestine, spleen, and bone marrow. In toxicity studies, mice treated with KF4 25 mg/kg weekly for four weeks showed an elevation in blood urea nitrogen and slower weight gain compared to lower doses or equivalent dose IgG. By histologic grading of tissue injury of the lung, kidney, liver, and heart, there was some evidence of liver injury with KF4 25 mg/kg, but in all tissues, injury was less than in control mice subjected to cecal ligation and puncture. In efficacy studies, KF4 doses as low as 0.5 mg/kg reduced the lung elastase activity of AAT-/- mice treated with 0.2 units of PPE. In this injury model, AAT-/- mice treated with KF4 1 mg/kg weekly, human purified AAT 60 mg/kg weekly, and combined KF4 and AAT treatment had less emphysema than mice treated with IgG 1 mg/kg weekly. However, the efficacy of KF4, AAT, or KF4 &amp; AAT was similar. While KF4 might be an alternative to AAT replacement, combined KF4 and AAT replacement does not confer additional benefit.</description><identifier>ISSN: 2372-952X</identifier><identifier>EISSN: 2372-952X</identifier><identifier>DOI: 10.15326/jcopdf.2024.0535</identifier><identifier>PMID: 39636054</identifier><language>eng</language><publisher>United States</publisher><ispartof>Chronic obstructive pulmonary diseases, 2024-11</ispartof><rights>JCOPDF © 2024.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39636054$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Devine, Andrew J</creatorcontrib><creatorcontrib>Smith, Noah J</creatorcontrib><creatorcontrib>Joshi, Rashika</creatorcontrib><creatorcontrib>Brooks-Patton, Brandon</creatorcontrib><creatorcontrib>Dunham, Jenna</creatorcontrib><creatorcontrib>Varisco, Ansley N</creatorcontrib><creatorcontrib>Goodman, Emily M</creatorcontrib><creatorcontrib>Fan, Qiang</creatorcontrib><creatorcontrib>Zingarelli, Basilia</creatorcontrib><creatorcontrib>Varisco, Brian M</creatorcontrib><title>KF4 Anti-Chymotrypsin-like Elastase 1 Antibody and Purified Alpha-1 Antitrypsin Have Similar but Not Additive Efficacy in Preventing Emphysema in Murine Alpha-1 Antitrypsin Deficiency</title><title>Chronic obstructive pulmonary diseases</title><addtitle>Chronic Obstr Pulm Dis</addtitle><description>Alpha-1 antitrypsin (AAT) deficiency is the most common genetic cause of emphysema. Chymotrypsin-like Elastase 1 (CELA1) is a serine protease neutralized by AAT and is important in emphysema progression. Cela1-deficiency is protective in a murine models of AAT-deficient emphysema. KF4 anti-CELA1 antibody prevented emphysema in porcine pancreatic elastase (PPE) and cigarette smoke models in wild type mice. We evaluated potential toxicities of KF4 and its ability to prevent emphysema in AAT deficiency. We found Cela1 protein expression in mouse lung, pancreas, small intestine, spleen, and bone marrow. In toxicity studies, mice treated with KF4 25 mg/kg weekly for four weeks showed an elevation in blood urea nitrogen and slower weight gain compared to lower doses or equivalent dose IgG. By histologic grading of tissue injury of the lung, kidney, liver, and heart, there was some evidence of liver injury with KF4 25 mg/kg, but in all tissues, injury was less than in control mice subjected to cecal ligation and puncture. In efficacy studies, KF4 doses as low as 0.5 mg/kg reduced the lung elastase activity of AAT-/- mice treated with 0.2 units of PPE. In this injury model, AAT-/- mice treated with KF4 1 mg/kg weekly, human purified AAT 60 mg/kg weekly, and combined KF4 and AAT treatment had less emphysema than mice treated with IgG 1 mg/kg weekly. However, the efficacy of KF4, AAT, or KF4 &amp; AAT was similar. While KF4 might be an alternative to AAT replacement, combined KF4 and AAT replacement does not confer additional benefit.</description><issn>2372-952X</issn><issn>2372-952X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNptkctOwzAQRS0EoqjwAWyQl2xS_IiTdFmVFhBPCZDYRY49pi55YSeV8mX8HukDxILVjGbuuZuD0CklIyo4iy6Wqqq1GTHCwhERXOyhI8ZjFowFe9v_sw_QifdLQghN4jih5BAN-DjiERHhEfq6nYd4UjY2mC66ompcV3tbBrn9ADzLpW-kB0w3iazSHZalxk-ts8aCxpO8Xshg-92R-FquAD_bwubS4axt8EPV4InWtrH9Y2aMVVJ1uE8-OVhBT5bveFbUi85DIdf3-76-hH_LL6HHLZSqO0YHRuYeTnZziF7ns5fpdXD3eHUzndwFioZUBAmnmqjIgBQsIiajIDNOuDaKCRmzZMyhP8ZjkhBOTUyYyjSNGc9kpliUUD5E59ve2lWfLfgmLaxXkOeyhKr1KadhJDglSdhH6TaqXOW9A5PWzhbSdSkl6UZZulWWrpWla2U9c7arb7MC9C_xI4h_A2fdlSY</recordid><startdate>20241126</startdate><enddate>20241126</enddate><creator>Devine, Andrew J</creator><creator>Smith, Noah J</creator><creator>Joshi, Rashika</creator><creator>Brooks-Patton, Brandon</creator><creator>Dunham, Jenna</creator><creator>Varisco, Ansley N</creator><creator>Goodman, Emily M</creator><creator>Fan, Qiang</creator><creator>Zingarelli, Basilia</creator><creator>Varisco, Brian M</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20241126</creationdate><title>KF4 Anti-Chymotrypsin-like Elastase 1 Antibody and Purified Alpha-1 Antitrypsin Have Similar but Not Additive Efficacy in Preventing Emphysema in Murine Alpha-1 Antitrypsin Deficiency</title><author>Devine, Andrew J ; Smith, Noah J ; Joshi, Rashika ; Brooks-Patton, Brandon ; Dunham, Jenna ; Varisco, Ansley N ; Goodman, Emily M ; Fan, Qiang ; Zingarelli, Basilia ; Varisco, Brian M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1415-831d0c6fea5260fb1eab303dfc25a72893efb17908031f702cbd1723babc26813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Devine, Andrew J</creatorcontrib><creatorcontrib>Smith, Noah J</creatorcontrib><creatorcontrib>Joshi, Rashika</creatorcontrib><creatorcontrib>Brooks-Patton, Brandon</creatorcontrib><creatorcontrib>Dunham, Jenna</creatorcontrib><creatorcontrib>Varisco, Ansley N</creatorcontrib><creatorcontrib>Goodman, Emily M</creatorcontrib><creatorcontrib>Fan, Qiang</creatorcontrib><creatorcontrib>Zingarelli, Basilia</creatorcontrib><creatorcontrib>Varisco, Brian M</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Chronic obstructive pulmonary diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Devine, Andrew J</au><au>Smith, Noah J</au><au>Joshi, Rashika</au><au>Brooks-Patton, Brandon</au><au>Dunham, Jenna</au><au>Varisco, Ansley N</au><au>Goodman, Emily M</au><au>Fan, Qiang</au><au>Zingarelli, Basilia</au><au>Varisco, Brian M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>KF4 Anti-Chymotrypsin-like Elastase 1 Antibody and Purified Alpha-1 Antitrypsin Have Similar but Not Additive Efficacy in Preventing Emphysema in Murine Alpha-1 Antitrypsin Deficiency</atitle><jtitle>Chronic obstructive pulmonary diseases</jtitle><addtitle>Chronic Obstr Pulm Dis</addtitle><date>2024-11-26</date><risdate>2024</risdate><issn>2372-952X</issn><eissn>2372-952X</eissn><abstract>Alpha-1 antitrypsin (AAT) deficiency is the most common genetic cause of emphysema. Chymotrypsin-like Elastase 1 (CELA1) is a serine protease neutralized by AAT and is important in emphysema progression. Cela1-deficiency is protective in a murine models of AAT-deficient emphysema. KF4 anti-CELA1 antibody prevented emphysema in porcine pancreatic elastase (PPE) and cigarette smoke models in wild type mice. We evaluated potential toxicities of KF4 and its ability to prevent emphysema in AAT deficiency. We found Cela1 protein expression in mouse lung, pancreas, small intestine, spleen, and bone marrow. In toxicity studies, mice treated with KF4 25 mg/kg weekly for four weeks showed an elevation in blood urea nitrogen and slower weight gain compared to lower doses or equivalent dose IgG. By histologic grading of tissue injury of the lung, kidney, liver, and heart, there was some evidence of liver injury with KF4 25 mg/kg, but in all tissues, injury was less than in control mice subjected to cecal ligation and puncture. In efficacy studies, KF4 doses as low as 0.5 mg/kg reduced the lung elastase activity of AAT-/- mice treated with 0.2 units of PPE. In this injury model, AAT-/- mice treated with KF4 1 mg/kg weekly, human purified AAT 60 mg/kg weekly, and combined KF4 and AAT treatment had less emphysema than mice treated with IgG 1 mg/kg weekly. However, the efficacy of KF4, AAT, or KF4 &amp; AAT was similar. While KF4 might be an alternative to AAT replacement, combined KF4 and AAT replacement does not confer additional benefit.</abstract><cop>United States</cop><pmid>39636054</pmid><doi>10.15326/jcopdf.2024.0535</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2372-952X
ispartof Chronic obstructive pulmonary diseases, 2024-11
issn 2372-952X
2372-952X
language eng
recordid cdi_crossref_primary_10_15326_jcopdf_2024_0535
source EZB-FREE-00999 freely available EZB journals; PubMed Central
title KF4 Anti-Chymotrypsin-like Elastase 1 Antibody and Purified Alpha-1 Antitrypsin Have Similar but Not Additive Efficacy in Preventing Emphysema in Murine Alpha-1 Antitrypsin Deficiency
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T00%3A15%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=KF4%20Anti-Chymotrypsin-like%20Elastase%201%20Antibody%20and%20Purified%20Alpha-1%20Antitrypsin%20Have%20Similar%20but%20Not%20Additive%20Efficacy%20in%20Preventing%20Emphysema%20in%20Murine%20Alpha-1%20Antitrypsin%20Deficiency&rft.jtitle=Chronic%20obstructive%20pulmonary%20diseases&rft.au=Devine,%20Andrew%20J&rft.date=2024-11-26&rft.issn=2372-952X&rft.eissn=2372-952X&rft_id=info:doi/10.15326/jcopdf.2024.0535&rft_dat=%3Cproquest_cross%3E3146531084%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3146531084&rft_id=info:pmid/39636054&rfr_iscdi=true